CNO (CNO) Q1 2026 Earnings Call Transcript

CNO Financial reported Q1 operating EPS of $1.05, up 33% year over year and 42% excluding significant items, with total NAP up 11% and book value per diluted share ex-AOCI up 5% to $38.98. Management reaffirmed 2026 guidance, highlighted a 13.1% trailing ROE and $77 million returned to shareholders, and said 2027 ROE ambitions may rise from the current 12% waypoint. The call also pointed to continued investment income growth (+6%), stronger Medicare supplement pricing approvals, and AI-driven efficiency gains in the call center.

Analysis

CNO is increasingly behaving like a compounding spread business rather than a purely cyclical insurer: the combination of persistent sales growth, agent-count expansion, and disciplined capital returns is creating a self-reinforcing earnings flywheel. The key second-order effect is that management’s willingness to keep buybacks active while maintaining a mid-band RBC ratio suggests excess capital is becoming a recurring rather than episodic source of EPS growth, which should support multiple stability even if top-line growth moderates.

The most underappreciated catalyst is the Medicare supplement repricing cycle. Because the closed block is roughly two-thirds of exposure, the approved rate step-up should meaningfully lift margins into late 2026, while the open block follows later in the year; that sequencing creates a visible earnings ramp rather than a one-quarter pop. That also creates an embedded hedge against claims drift, which reduces the probability that near-term medical cost noise forces a reset to guidance.

The market may be underpricing the duration benefit from higher book yields. With new money still north of 6% and asset growth continuing, net investment income should keep compounding even if sales merely stay flat. The bigger risk is not credit spread volatility; it is equity-market-driven statutory noise, because lower AOCI-linked equity values can temporarily pressure RBC and capital flexibility, though management has already signaled that this should unwind if markets normalize.

Contrarian take: the stock may not be a pure re-rating story yet because the company is intentionally refusing to lift formal long-term targets. That restraint can read as conservatism, but it also gives them optionality to beat later, which is usually better for the share path than frequent target resets. The main reversal trigger is a deterioration in Medicare claims or a sharper retracement in equity markets that delays capital deployment and blunts the buyback cadence.

Key Decisions for Investors

• Long CNO common into the next 3-6 months: the Medicare rate increases and continued buybacks create a favorable earnings slope; downside is limited unless claims or capital volatility worsen materially.
• Buy CNO Jan-2027 calls / sell lower-strike calls as a modest upside structure: target a re-rating on visible 2H26 margin improvement with defined risk if the market discounts the ROE uplift.
• Pair trade: long CNO / short a higher-beta life insurer with more rate-sensitive earnings and weaker capital return discipline over the next 1-2 quarters; CNO has better self-help and more visible earnings momentum.
• Add on dips if equity markets fall and RBC noise compresses the stock: this should be a transient mark-to-market issue rather than a thesis break, with potential for a fast snapback as markets recover.
• Take partial profits only if the stock starts pricing in a formal ROE target increase before year-end: that would reduce the asymmetry, since management is explicitly deferring the formal catalyst.